Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 – коварный тандем: возможности дополнительной органопротективной терапии
Стаценко М.Е., Туркина С.В., Шилина Н.Н. Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 – коварный тандем: возможности дополнительной органопротективной терапии. Consilium Medicum. 2016; 18 (5): 103–109. DOI: 10.26442/2075-1753_2016.5.103-109
________________________________________________
Statsenkо M.E., Turkina S.V., Shilina N.N. Liver damage in patients with ischemic chronic heart and type 2 diabetes – a treacherous tandem: possible additional organoprotective therapy. Consilium Medicum. 2016; 18 (5):103–109. DOI: 10.26442/2075-1753_2016.5.103-109
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представлены данные об особенностях структурно-функционального состояния печени у пациентов с хронической сердечной недостаточностью (ХСН) ишемического генеза и сахарным диабетом типа 2 (СД 2). Продемонстрированы дополнительные возможности органопротективной (гепато-, кардиопротективной) терапии таурином в составе комбинированной терапии пациентов с ХСН и СД 2. Отмечены дополнительные гипогликемизирующие, липидснижающие возможности таурина, положительное влияние на выраженность инсулинорезистентности.
Ключевые слова: хроническая сердечная недостаточность, сахарный диабет типа 2, таурин, структурно-функциональное состояние печени, углеводный и липидный обмен, инсулинорезистентность, маркеры фиброза.
Ключевые слова: хроническая сердечная недостаточность, сахарный диабет типа 2, таурин, структурно-функциональное состояние печени, углеводный и липидный обмен, инсулинорезистентность, маркеры фиброза.
________________________________________________
The presented data on the structure and functional state of the liver in patients with ischemic chronic heart failure (CHF) and type 2 diabetes. Showcased additional opportunities organoprotective (hepato-, cardioprotective) taurine therapy in combination therapy in patients with CHF and type 2 diabetes. Noted additional hypoglycemic, lipid-lowering capabilities of taurine, a positive effect on the severity of insulin resistance.
Key words: chronic heart failure, type 2 diabetes, taurine, structural-functional state of the liver, carbohydrate and lipid metabolism, insulin resistance, fibrosis markers.
Key words: chronic heart failure, type 2 diabetes, taurine, structural-functional state of the liver, carbohydrate and lipid metabolism, insulin resistance, fibrosis markers.
Полный текст
Список литературы
1. Nieminen MS, Brutsaert D, Dickstein K et al. Euro Heart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725–36.
2. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699–703.
3. Sarma S, Mentz RJ, Kwasny MJ et al. On behalf of the EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194–202.
4. Shengbo Y. The prevalence and prognostic value of liver function abnormalities in patients with chronic systolic heart failure. Heart 2011; 97: А215.
5. Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1724–45.
6. Ekstedt M, Franz´en LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
7. Dogan S, Celikbilek M, Yilmaz YK et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 298–304.
8. Kim D, Kim WR, Kim HJ, Terry M. Therneau. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (Issue 4): 1357–65.
9. Ban CR, Twigg SM. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575–96.
10. Dries DL, Sweitzer NK, Drazner MH et al. Рrognostic Impact of Diabetes Mellitus in Patients With Heart Failure According to the Etiology of Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2001; 38 (2): 421–8.
11. Xu YJ, Saini HK, Zhang M et al. MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res 2006; 72: 163–74.
12. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000; 18: 305–18.
13. Abebe W, Mozaffari MS. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 2011; 1 (3): 293–311.
14. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Винникова А.А. Место таурина в комплексном лечении пациентов с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Рус. мед. журн. 2015; 23 (8): 472–6. / Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. Mesto taurina v kompleksnom lechenii patsientov s khronicheskoi serdechnoi nedostatochnost'iu i sakharnym diabetom 2 tipa. Rus. med. zhurn. 2015; 23 (8): 472–6. [in Russian]
15. Abd El-Kader SM, El-Den Ashmaw EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7 (6): 846–58.
16. Gentile CL, Nivala AM, Gonzales JC et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011; 301 (6): R1710–R1722.
17. Balkan J, Doğru-Abbasoğlu S, Kanbağli O et al. Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 2001; 20: 251–4.
18. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001; 17: 330–46.
19. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Косивцова М.А. Особенности гепатокардиальных взаимоотношений у пациентов с хронической сердечной недостаточностью и нарушениями углеводного обмена: возможности дополнительной терапии. Рус. мед. журн. 2015; 23 (21): 1293–7. / Statsenko M.E., Turkina S.V., Shilina N.N., Kosivtsova M.A. Osobennosti gepatokardial'nykh vzaimootnoshenii u patsientov s khronicheskoi serdechnoi nedostatochnost'iu i narusheniiami uglevodnogo obmena: vozmozhnosti dopolnitel'noi terapii. Rus. med. zhurn. 2015; 23 (21): 1293–7. [in Russian]
20. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7 (81): 1–94. / Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14; 7 (81): 1–94. [in Russian]
21. Алгоритмы специализированной медицинской помощи больным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2015. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. M., 2015. [in Russian]
22. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33–8.
23. Angulo P, Hui JM, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846–54.
24. Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek 2011; 68 (6): 334–8.
25. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 1. Doi:10.1016/j.jhep.2015.04.006.
26. Yokogoshi H, Mochizuki H, Nanami K et al. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 1999; 129: 1705–12.
27. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303–13.
28. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398–403.
29. Carneiro EM, Latorraca MQ, Araujo E et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochemistry 2009; 20: 503–11.
30. Maturo J, Kulakowski EC. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37 (19): 3755–60.
31. Gavrovskaya LK, Ryzhova OV, Safonova AF et al. Protective effect of taurine on rats with experimental insulin-dependent diabetes mellitus. Bull Exp Biol Med 2008; 146 (2): 226–8.
32. Nakaya Y, Minami A, Harada N et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71 (1): 54–8.
33. Wu N, Lu Y, He B et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo Diabetes Res Clin Pract 2010; 90 (3): 288–96.
2. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699–703.
3. Sarma S, Mentz RJ, Kwasny MJ et al. On behalf of the EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194–202.
4. Shengbo Y. The prevalence and prognostic value of liver function abnormalities in patients with chronic systolic heart failure. Heart 2011; 97: А215.
5. Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1724–45.
6. Ekstedt M, Franz´en LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
7. Dogan S, Celikbilek M, Yilmaz YK et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 298–304.
8. Kim D, Kim WR, Kim HJ, Terry M. Therneau. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (Issue 4): 1357–65.
9. Ban CR, Twigg SM. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575–96.
10. Dries DL, Sweitzer NK, Drazner MH et al. Рrognostic Impact of Diabetes Mellitus in Patients With Heart Failure According to the Etiology of Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2001; 38 (2): 421–8.
11. Xu YJ, Saini HK, Zhang M et al. MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res 2006; 72: 163–74.
12. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000; 18: 305–18.
13. Abebe W, Mozaffari MS. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 2011; 1 (3): 293–311.
14. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Винникова А.А. Место таурина в комплексном лечении пациентов с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Рус. мед. журн. 2015; 23 (8): 472–6. / Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. Mesto taurina v kompleksnom lechenii patsientov s khronicheskoi serdechnoi nedostatochnost'iu i sakharnym diabetom 2 tipa. Rus. med. zhurn. 2015; 23 (8): 472–6. [in Russian]
15. Abd El-Kader SM, El-Den Ashmaw EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7 (6): 846–58.
16. Gentile CL, Nivala AM, Gonzales JC et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011; 301 (6): R1710–R1722.
17. Balkan J, Doğru-Abbasoğlu S, Kanbağli O et al. Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 2001; 20: 251–4.
18. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001; 17: 330–46.
19. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Косивцова М.А. Особенности гепатокардиальных взаимоотношений у пациентов с хронической сердечной недостаточностью и нарушениями углеводного обмена: возможности дополнительной терапии. Рус. мед. журн. 2015; 23 (21): 1293–7. / Statsenko M.E., Turkina S.V., Shilina N.N., Kosivtsova M.A. Osobennosti gepatokardial'nykh vzaimootnoshenii u patsientov s khronicheskoi serdechnoi nedostatochnost'iu i narusheniiami uglevodnogo obmena: vozmozhnosti dopolnitel'noi terapii. Rus. med. zhurn. 2015; 23 (21): 1293–7. [in Russian]
20. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14; 7 (81): 1–94. / Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14; 7 (81): 1–94. [in Russian]
21. Алгоритмы специализированной медицинской помощи больным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2015. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. M., 2015. [in Russian]
22. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33–8.
23. Angulo P, Hui JM, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846–54.
24. Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek 2011; 68 (6): 334–8.
25. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 1. Doi:10.1016/j.jhep.2015.04.006.
26. Yokogoshi H, Mochizuki H, Nanami K et al. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 1999; 129: 1705–12.
27. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303–13.
28. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398–403.
29. Carneiro EM, Latorraca MQ, Araujo E et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochemistry 2009; 20: 503–11.
30. Maturo J, Kulakowski EC. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37 (19): 3755–60.
31. Gavrovskaya LK, Ryzhova OV, Safonova AF et al. Protective effect of taurine on rats with experimental insulin-dependent diabetes mellitus. Bull Exp Biol Med 2008; 146 (2): 226–8.
32. Nakaya Y, Minami A, Harada N et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71 (1): 54–8.
33. Wu N, Lu Y, He B et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo Diabetes Res Clin Pract 2010; 90 (3): 288–96.
________________________________________________
1. Nieminen MS, Brutsaert D, Dickstein K et al. Euro Heart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725–36.
2. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699–703.
3. Sarma S, Mentz RJ, Kwasny MJ et al. On behalf of the EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194–202.
4. Shengbo Y. The prevalence and prognostic value of liver function abnormalities in patients with chronic systolic heart failure. Heart 2011; 97: А215.
5. Ballestri S, Lonardo A, Bonapace S et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (7): 1724–45.
6. Ekstedt M, Franz´en LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
7. Dogan S, Celikbilek M, Yilmaz YK et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27 (3): 298–304.
8. Kim D, Kim WR, Kim HJ, Terry M. Therneau. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (Issue 4): 1357–65.
9. Ban CR, Twigg SM. Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 2008; 4 (3): 575–96.
10. Dries DL, Sweitzer NK, Drazner MH et al. Рrognostic Impact of Diabetes Mellitus in Patients With Heart Failure According to the Etiology of Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2001; 38 (2): 421–8.
11. Xu YJ, Saini HK, Zhang M et al. MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res 2006; 72: 163–74.
12. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids 2000; 18: 305–18.
13. Abebe W, Mozaffari MS. Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 2011; 1 (3): 293–311.
14. Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. Mesto taurina v kompleksnom lechenii patsientov s khronicheskoi serdechnoi nedostatochnost'iu i sakharnym diabetom 2 tipa. Rus. med. zhurn. 2015; 23 (8): 472–6. [in Russian]
15. Abd El-Kader SM, El-Den Ashmaw EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7 (6): 846–58.
16. Gentile CL, Nivala AM, Gonzales JC et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011; 301 (6): R1710–R1722.
17. Balkan J, Doğru-Abbasoğlu S, Kanbağli O et al. Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol 2001; 20: 251–4.
18. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001; 17: 330–46.
19. Statsenko M.E., Turkina S.V., Shilina N.N., Kosivtsova M.A. Osobennosti gepatokardial'nykh vzaimootnoshenii u patsientov s khronicheskoi serdechnoi nedostatochnost'iu i narusheniiami uglevodnogo obmena: vozmozhnosti dopolnitel'noi terapii. Rus. med. zhurn. 2015; 23 (21): 1293–7. [in Russian]
20. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14; 7 (81): 1–94. [in Russian]
21. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. M., 2015. [in Russian]
22. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33–8.
23. Angulo P, Hui JM, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846–54.
24. Walczewska M, Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl Lek 2011; 68 (6): 334–8.
25. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 1. Doi:10.1016/j.jhep.2015.04.006.
26. Yokogoshi H, Mochizuki H, Nanami K et al. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 1999; 129: 1705–12.
27. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303–13.
28. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398–403.
29. Carneiro EM, Latorraca MQ, Araujo E et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochemistry 2009; 20: 503–11.
30. Maturo J, Kulakowski EC. Taurine binding to the purified insulin receptor. Biochem Pharmacol 1988; 37 (19): 3755–60.
31. Gavrovskaya LK, Ryzhova OV, Safonova AF et al. Protective effect of taurine on rats with experimental insulin-dependent diabetes mellitus. Bull Exp Biol Med 2008; 146 (2): 226–8.
32. Nakaya Y, Minami A, Harada N et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000; 71 (1): 54–8.
33. Wu N, Lu Y, He B et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo Diabetes Res Clin Pract 2010; 90 (3): 288–96.
Авторы
М.Е.Стаценко*, С.В.Туркина, Н.Н.Шилина
ГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
*mestatsenko@rambler.ru
ГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
*mestatsenko@rambler.ru
________________________________________________
M.E.Statsenkо*, S.V.Turkina, N.N.Shilina
Volgograd State Medical University of Ministry of Health of the Russian Federation. 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
*mestatsenko@rambler.ru
Volgograd State Medical University of Ministry of Health of the Russian Federation. 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
*mestatsenko@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.